Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (276)	9/29/2004 5:38:21 PM
From: Icebrg	Read Replies (2) \| Respond to of 946

Arsenic may have role in leukaemia treatment [Nothing new here really, apart from the location of the investigators. Who knows - maybe Iran will beat the US to an approval of Trisenox in first-line APL therapy. But I doubt it will result in any revenue dollars on CTIC's books.] Last Updated: 2004-09-29 11:43:23 -0400 (Reuters Health) LONDON (Reuters) - It's best known as a weed-killer or a favourite weapon of murderous old ladies, but arsenic could find a new role as a mainstream treatment for leukaemia, Iranian researchers said on Wednesday. They were so impressed with trials involving patients with a rare type of leukaemia that they have suggested it could be used as an initial treatment. "There have been a few studies done using arsenic...but we are the first group to suggest that it is acceptable as a first-line treatment," Dr. Ardeshir Ghavamzadeh of Tehran University of Medical Sciences said in a statement. In a study reported at a European oncology meeting in Geneva, the researchers said arsenic was effective against acute promyeloctytic leukaemia, or APL, a cancer of the blood and bone marrow that affects myeloid blood cells. APL, which affects 20,000 people worldwide, is most common in the elderly. It is a subtype of acute myeloid leukaemia, the most common form of adult leukaemia. Ninety percent of 63 patients who had not been previously treated for the illness had complete remission after two courses of the arsenic treatment. More than 88 percent were still alive with a mean survival time of nearly 34 months. "What this means is that we now have the possibility of offering APL patients a new first-line treatment that avoids conventional chemotherapy," said Ghavamzadeh. Arsenic compounds have been used in medicine for thousands of years, dating back to the ancient Chinese and Romans. In the 1980s, Chinese researchers first tried it in leukaemia after discovering it was an active ingredient in some traditional Chinese medicines, according to the researchers. The poison was made famous in the 1944 film "Arsenic and Old Lace" staring Cary Grant. It was based on a stage play of the same name.